Commentary

Boxed warnings: Legal risks that many physicians never see coming


 

What can physicians do to minimize boxed warning problems?

Physicians should periodically review the product labels for drugs they commonly prescribe, including drugs they’ve prescribed for a long time. Prescription renewal requests can be used as a prompt to check for changes in a patient’s condition or other medications that might place a patient in the target population of a boxed warning. Physicians can subscribe to newsletters that announce and discuss significant product label changes, including alerts directly from the FDA. Physicians may also enlist their office staff to find and review boxed warnings for drugs being prescribed, noting which ones should require a conversation with any patient who has been or will be receiving this drug. They may want to make explicit mention in their encounter record that a boxed warning, medication guide, or overall risk-benefit assessment has been discussed.

Summary

The nature of boxed warnings, the means by which they are disseminated, and their role in clinical practice are all in great need of improvement. Until that occurs, boxed warnings offer some, but only very limited, help to patients and physicians who struggle to understand the risks of medications.

Dr. Axelsen is professor in the departments of pharmacology, biochemistry, and biophysics, and of medicine, infectious diseases section, University of Pennsylvania, Philadelphia. He disclosed no relevant financial relationships. A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Fraudulent misbranding of PPE nets $22 million settlement
Federal Practitioner
Study finds paying people to participate in clinical trials is not unethical
Federal Practitioner
New data illustrate pandemic pivot to telehealth by patients, physicians
Federal Practitioner
Telehealth for heart failure during pandemic shown effective, safe
Federal Practitioner
COVID-19: Can doctors refuse to see unvaccinated patients?
Federal Practitioner
PA defends against license suspension for COVID treatment
Federal Practitioner
Survey spotlights double-edged sword for minority cardiologists
Federal Practitioner
Social determinants of health may drive CVD risk in Black Americans
Federal Practitioner
Risk-based antenatal type-and-screen blood testing safe and economical
Federal Practitioner
80% of Americans research recommendations post-visit
Federal Practitioner